Dapagliflozin Attenuates Myocardial Inflammation and Apoptosis after Coronary Microembolization in Rats by Regulating the SIRT1/NF-κB Signaling Pathway
Frontiers in Bioscience-Landmark · 2025
DOI: 10.31083/fbl27082 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Bioscience-Landmark, 2025. Verfasst von Tao Li und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, The First Affiliated Hospital of Guangxi Medical University, 530021 Nanning, Guangxi, China. Hauptthemen laut MEDLINE: Glucosides, Sirtuin 1, Apoptosis, NF-kappa B. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
Coronary microembolization (CME) often occurs as a serious complication during or after percutaneous coronary intervention (PCI), leading to an impairment in heart function, inflammation, and cell death. Dapagliflozin (DAPA) has been shown to have cardioprotective effects. However, its role and exact mechanism in CME remains unclear.
Methods
A preclinical CME model was developed via the administration of microspheres into the left ventricle. In an in vitro model, the CME-created microenvironment was observed by using lipopolysaccharide (LPS) with hypoxic induction on H9C2 cardiomyocytes. Before developing both experimental models, DAPA or the sirtuin 1 (SIRT1) inhibitor “EX-527” was administered. Echocardiography, histological examination, and molecular and immunological assays were carried out to assess the levels of cardiac tissue or cardiomyocyte damage, inflammation, and apoptosis.
Results
Heart dysfunction and tissue damage caused by CME can be alleviated by pre-treatment with DAPA, which also reduces myocardial inflammation and apoptosis. Moreover, both experimental studies have depicted that DAPA can upregulate the SIRT1 level and downregulate the acetylation and phosphorylation levels of nuclear factor kappa-B (NF-κB) p65. This effect inhibits the induction of NF-κB signaling and mitigates cardiomyocyte damage. However, DAPA’s cardioprotective effect was reversed when co-treated with EX-527.
Conclusions
DAPA reduces myocardial damage caused by CME by suppressing myocarditis and apoptosis via the SIRT1/NF-κB axis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, The First Affiliated Hospital of Guangxi Medical University, 530021 Nanning, Guangxi, China.
- Department of Cardiology, Affiliated Liutie Central Hospital of Guangxi Medical University, 545007 Liuzhou, Guangxi, China.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Li, T., Luo, C. J., Yi, Z. Q., & Li, L. (2025). Dapagliflozin Attenuates Myocardial Inflammation and Apoptosis after Coronary Microembolization in Rats by Regulating the SIRT1/NF-κB Signaling Pathway. Frontiers in Bioscience-Landmark. https://doi.org/10.31083/fbl27082
Vancouver
Li T, Luo CJ, Yi ZQ, Li L. Dapagliflozin Attenuates Myocardial Inflammation and Apoptosis after Coronary Microembolization in Rats by Regulating the SIRT1/NF-κB Signaling Pathway. Frontiers in Bioscience-Landmark. 2025. doi:10.31083/fbl27082
BibTeX
@article{Li2025,
author = {Li, Tao and Luo, Chang-Jun and Yi, Ze-Qiang and Li, Lang},
title = {Dapagliflozin Attenuates Myocardial Inflammation and Apoptosis after Coronary Microembolization in Rats by Regulating the SIRT1/NF-κB Signaling Pathway},
journal = {Frontiers in Bioscience-Landmark},
year = {2025},
doi = {10.31083/fbl27082}
}
EUVIMED